Literature DB >> 9758686

A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software.

A C Heatherington1, P Vicini, H Golde.   

Abstract

This paper presents a detailed comparison of the kinetic analysis software packages SAAM II and PCNonlin/WinNonlin, based on benchmark modeling problems reported in "Pharmacokinetic andPharmacodynamic Data Analysis: Concepts and Applications" (Gabrielsson and Weiner, 1994) and seven additional models. For each model, both software packages were presented with identical implementations. Models were initially executed in PCNonlin or WinNonlin and automated comparisons with SAAM II made using Microsoft Test. Models investigated included one- and multicompartment models with nonlinearities, multiple inputs and samples, multiple simultaneous experiments, and linear equations. Maximum number of compartments, data sets, and parameters were 9, 5, and 10, respectively. We compared 88 different models, many of them in different configurations, e.g., different weighting schemes or different parameter limits. The total number of attempted comparisons between SAAM II and PCNonlin was 161, of which 142 executed without problems. Parameter estimates, their precision (standard errors), and model predictions were compared; a difference of 1% or less was considered "agreement". Observed differences, mainly in parameter standard errors, can be accounted for in terms of different optimization algorithms, convergence criteria, and individual capabilities. In general, there was good agreement (<1% difference) between SAAM II and PCNonlin in terms of parameter estimates and model predictions. However, due to differences in the optimization procedure, parameter standard errors showed considerable differences. Additionally, there were differences when multiple data sets were fitted, indicating the importance of different fitting procedures for interpreting multiple kinetic data sets. The full results of the comparison and the model files in SAAM II and PCNonlin/WinNonlin formats are available from the authors.

Entities:  

Mesh:

Year:  1998        PMID: 9758686     DOI: 10.1021/js9603562

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Pharmacokinetic studies in patients on continuous renal replacement therapies.

Authors:  U F Kroh
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

2.  Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.

Authors:  Melvin Berger; Paul J Pinciaro; Arthur Althaus; Mark Ballow; Akhilesh Chouksey; James Moy; Hans Ochs; Mark Stein
Journal:  J Clin Immunol       Date:  2009-12-08       Impact factor: 8.317

3.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Authors:  Deni Hardiansyah; Christian Maass; Ali Asgar Attarwala; Berthold Müller; Peter Kletting; Felix M Mottaghy; Gerhard Glatting
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

5.  Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data.

Authors:  Gregory Z Ferl; Xiaoli Zhang; Hsiao-Ming Wu; Michael C Kreissl; Sung-Cheng Huang
Journal:  J Nucl Med       Date:  2007-11-15       Impact factor: 10.057

6.  A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.

Authors:  Melvin Berger
Journal:  J Clin Immunol       Date:  2007-10-02       Impact factor: 8.317

7.  Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳s disease.

Authors:  Qian Guo; Xiaoyao Zheng; Peng Yang; Xiaoying Pang; Kang Qian; Pengzhen Wang; Shuting Xu; Dongyu Sheng; Liuchang Wang; Jinxu Cao; Wei Lu; Qizhi Zhang; Xinguo Jiang
Journal:  Acta Pharm Sin B       Date:  2018-12-30       Impact factor: 11.413

8.  CYP3A5*3 and SLCO1B1 c.521T&gt;C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin.

Authors:  Jin-Woo Park; Jong-Min Kim; Hwa-Young Lee; Jihyeon Noh; Kyoung-Ah Kim; Ji-Young Park
Journal:  Pharmaceutics       Date:  2022-07-18       Impact factor: 6.525

9.  A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.

Authors:  James S McCarthy; Thomas Rückle; Elhadj Djeriou; Cathy Cantalloube; Daniel Ter-Minassian; Mark Baker; Peter O'Rourke; Paul Griffin; Louise Marquart; Rob Hooft van Huijsduijnen; Jörg J Möhrle
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979

10.  Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy.

Authors:  Juan C Velasquez; Nick Goeden; Skyla M Herod; Alexandre Bonnin
Journal:  ACS Chem Neurosci       Date:  2016-01-30       Impact factor: 4.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.